The Value of Access: Clinical and Economic Impacts of New Therapies for Three Hematologic Cancers
This paper examines how pre-existing healthcare challenges and the pandemic affected blood cancer patients’ care, plus how overcoming the barriers to care could benefit patients and society.
How has lack of access to timely diagnosis and care impacted patients’ health and their economic contributions to Canada? What are the major barriers to accessing therapies, and what can be done to remove the barriers? If access to care were improved, how many life-years lost would be averted and what would be the increase in economic contributions to Canada?
Read the impact paper to get our full analysis.
Cette publication est disponible en français.
A shock to the healthcare system
The potential impact of increased therapy access
Clinical and economic burden of blood cancer and the pandemic
Measuring the clinical and economic costs of blood cancers
Quantifying the benefits of enhanced access: Modelling results
Overcoming access challenges to deliver new blood cancer therapies
Conclusion and insights
Appendix A: Background and methodology
Appendix B: Bibliography
There are no reviews yet.